Anthony Olofintuyi, MD
Internal Medicine · Columbus, GANPI 1144384827
Payments from drug & device makers
Across 709 payments — averaging $1682.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vertex$394K
- Eli Lilly$287K
- Alnylam Pharmaceuticals Inc.$262K
- GSK$72K
- Amgen$70K
- Currax Pharmaceuticals LLC$51K
- plus $56K from 10 others
Across 22 payments — averaging $897.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$17K
- GSK$3K
What the payments were for
- Travel & lodging$3,26073%
- Food & beverage$1,11725%
- Gifts$591%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vertex | 8 | $394,490 |
| Eli Lilly | 2 | $287,148 |
| Alnylam Pharmaceuticals Inc. | 634 | $261,918 |
| GSK | 15 | $72,082 |
| Amgen | 2 | $70,172 |
| Currax Pharmaceuticals LLC | 16 | $50,697 |
| Chiesi USA, Inc. | 6 | $24,604 |
| Modernatx, Inc. | 9 | $16,155 |
| Vanda Pharmaceuticals Inc. | 1 | $10,323 |
| Orasure Technologies Inc. | 3 | $4,590 |
| AstraZeneca | 8 | $310 |
| Mannkind Corporation | 1 | $59 |
| Novartis | 1 | $54 |
| Novo Nordisk | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
| Pfizer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$125
How this compares
$1,192,649 in reported general payments places this provider in the 95th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 115 | $119,652 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 71 | $48,124 |
| EliquisApixaban | 69 | $39,705 |
| RybelsusSemaglutide | 29 | $35,955 |
| Tresiba Flextouch U-200Insulin Degludec | 47 | $35,651 |
| LinzessLinaclotide | 60 | $33,112 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 45 | $28,868 |
| EntrestoSacubitril/Valsartan | 30 | $26,085 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 779 | $16,302 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 14 | $16,217 |
| JanuviaSitagliptin Phosphate | 19 | $15,275 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $9,392 |
| JanumetSitagliptin Phos/Metformin Hcl | 14 | $7,708 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 56 | $7,189 |
| XareltoRivaroxaban | 11 | $6,305 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6 | $23 | $171,823158 claims |
| GSKTrelegy Ellipta | $72,082 | $48,12471 claims |
| PfizerEliquis | $11 | $39,70569 claims |
| AstraZenecaBreztri Aerosphere | $310 | $28,86845 claims |
| NovartisEntresto | $54 | $26,08530 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Columbus
- Joshua SamrajColumbus$241K
- Ricardo AlvarezColumbus$199K
- Paul BradleySavannah$76.4M
- Kimball JohnsonAtlanta$51.1M
- Bram WieskopfWoodstock$21.9M
- Dwight BlakeUnion City$13.3M
- Charlotte Grayson-MathisFayetteville$9.6M
- Christopher RecknorGainesville$9.2M
- James HarperJohns Creek$9.2M
- Robert Springer IiiAtlanta$5.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.